Resistance to vemurafenib resulting from a novel mutation in the BRAFV 600 E kinase domain
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Resistance to the BRAF inhibitor vemurafenib poses a significant problem for the treatment of BRAFV 600 E‐positive melanomas. It is therefore critical to prospectively identify all vemurafenib resistance mechanisms prior to their emergence in the clinic. The vemurafenib resistance mechanisms described to date do not result from secondary mutations within BRAFV 600E. To search for possible mutations within BRAFV 600E that can confer drug resistance, we developed a systematic experimental approach involving targeted saturation mutagenesis, selection of drug‐resistant variants, and deep sequencing. We identified a single nucleotide substitution (T 1514 A, encoding L 505 H) that greatly increased drug resistance in cultured cells and mouse xenografts. The kinase activity of BRAFV 600 E/L 505 H was higher than that of BRAFV 600 E, resulting in cross‐resistance to a MEK inhibitor. However, BRAFV 600 E/L 505 H was less resistant to several other BRAF inhibitors whose binding sites were further from L 505 than that of PLX 4720. Our results identify a novel vemurafenib‐resistant mutant and provide insights into the treatment for melanomas bearing this mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 2×
“Interestingly, a search of the Catalogue of Somatic Mutations in Cancer (COSMIC) database (Forbes et al., 2011) revealed that the T1514A mutation was recently found in an individual with prostate cancer (Barbieri et al., 2012), suggesting that the elevated kinase activity of BRAFL505H may…”
BackgroundRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 2×
“, 2012) and generation of aberrantly spliced BRAFV600E variants (Poulikakos et al., 2011).”
BackgroundDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240 · cited 1×
“…all relevant single mutants (because of sampling limitations and biases in random mutagenesis), or (ii) directed mutagenesis based on results from related targets (e.g., gatekeeper mutations in protein kinases) that do not broadly sample sequence space (reviewed in Warmuth et al., 2007).”
Background
Cited by
Deep mutational scanning: a new style of protein science
Fowler, D. M., & Fields, S. (2014) · Nature Methods · doi:10.1038/nmeth.3027 · Cited by 1,287
PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.037 · Cited by 168
Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
“Mirroring the clinical paradigm of acquired Vemurafenib (from now on indicated as PLX4032) resistance [42,43], we used the well characterized BRAF-mutated A375 metastatic cell line, and two independent isogenic metastatic melanoma cell models of acquired resistance (PLX4032-sensitive: 451-LU or M1617 and PLX4032-resis…”
Method
Metadata
- Authors
- Wagenaar, T. R., Ma, L., Roscoe, B., Park, S. M., Bolon, D. N., & Green, M. R.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2013-10-15
- Volume
- 27
- Issue
- 1
- Pages
- 124-133
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2096878348
- Cited by
- 59
- References
- 4
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to vemurafenib resulting from a novel mutation in the BRAFV 600 E kinase domain. https://app.cochat.ai/papers/10.1111/pcmr.12171
- The paper
- Wagenaar, T. R., Ma, L., Roscoe, B., Park, S. M., Bolon, D. N., & Green, M. R. (2014). Resistance to vemurafenib resulting from a novel mutation in the BRAFV 600 E kinase domain. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.12171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.